CytomX Therapeutics, Inc. (CTMX) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1238937,
    "name": "CytomX Therapeutics, Inc.",
    "stock_name": "CytomX Therapeutics, Inc.",
    "full_name": "CytomX Therapeutics, Inc.",
    "name_url": "stocks-analysis/cytomx-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "4.08",
    "chg": 0.27,
    "chgp": "7.09%",
    "dir": 1,
    "prev_price": "3.81",
    "mcapval": "359.51",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US23284F1057",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "3.69 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cytomx-therapeutics-inc-1238937-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "CytomX Therapeutics Hits New 52-Week High of $4.62, Up 157%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cytomx-therapeutics-hits-new-52-week-high-of-462-up-157-3680188",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CytomXTherapeut_priceRelatedfactors_3680188.png",
        "date": "2025-11-07 16:09:15",
        "description": "CytomX Therapeutics, Inc. has achieved a new 52-week high, reflecting a substantial increase in stock performance over the past year. The company, operating in the Pharmaceuticals & Biotechnology sector, boasts strong financial metrics, including a notable return on equity and a unique financial structure, underscoring its competitive position."
      },
      {
        "title": "CytomX Therapeutics Hits New 52-Week High of $4.18, Up 150.92%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cytomx-therapeutics-hits-new-52-week-high-of-418-up-15092-3674053",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CytomXTherapeut_priceRelatedfactors_3674053.png",
        "date": "2025-11-05 16:49:25",
        "description": "CytomX Therapeutics, Inc. achieved a new 52-week high of USD 4.18 on November 4, 2025, reflecting a significant annual stock performance increase. The company, with a market cap of USD 360 million, demonstrates strong financial metrics, including a favorable P/E ratio and a high return on equity."
      },
      {
        "title": "CytomX Therapeutics Hits New 52-Week High at $4.16",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cytomx-therapeutics-hits-new-52-week-high-at-416-3671527",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CytomXTherapeut_priceRelatedfactors_3671527.png",
        "date": "2025-11-04 17:59:44",
        "description": "CytomX Therapeutics, Inc. achieved a new 52-week high of USD 4.16 on November 3, 2025, reflecting a 141.1% increase over the past year. With a market cap of USD 360 million, the company demonstrates strong financial metrics, including a 40.02% return on equity and a debt-to-equity ratio of -1.27."
      },
      {
        "title": "CytomX Therapeutics Hits New 52-Week High at $3.51, Up 109.82%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cytomx-therapeutics-hits-new-52-week-high-at-351-up-10982-3622828",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CytomXTherapeut_priceRelatedfactors_3622828.png",
        "date": "2025-10-15 17:07:52",
        "description": "CytomX Therapeutics, Inc. achieved a new 52-week high of USD 3.51 on October 14, 2025, marking a significant increase from its previous low. With a market cap of USD 360 million, the company demonstrates strong profitability and a solid balance sheet, reflecting its growth in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "CytomX Therapeutics Hits New 52-Week High of $3.48, Up 105.52%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cytomx-therapeutics-hits-new-52-week-high-of-348-up-10552-3588403",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CytomXTherapeut_priceRelatedfactors_3588403.png",
        "date": "2025-10-02 22:39:19",
        "description": "CytomX Therapeutics, Inc. achieved a new 52-week high of USD 3.48 on October 1, 2025, reflecting a 105.52% increase over the past year. With a market capitalization of USD 360 million, the company shows strong financial metrics, including a P/E ratio of 10.00 and a return on equity of 40.02%."
      },
      {
        "title": "CytomX Therapeutics Hits New 52-Week High at $3.28",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cytomx-therapeutics-hits-new-52-week-high-at-328-3586063",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CytomXTherapeut_priceRelatedfactors_3586063.png",
        "date": "2025-10-01 16:42:32",
        "description": "CytomX Therapeutics, Inc. has achieved a new 52-week high of USD 3.28, reflecting a 95.71% increase over the past year. With a market capitalization of USD 360 million and a P/E ratio of 10.00, the company showcases strong financial health and effective capital management."
      },
      {
        "title": "CytomX Therapeutics Hits New 52-Week High of $3.25, Up 77.91%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cytomx-therapeutics-hits-new-52-week-high-of-325-up-7791-3579381",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/CytomXTherapeut_priceRelatedfactors_3579381.png",
        "date": "2025-09-29 14:29:15",
        "description": "CytomX Therapeutics, Inc. achieved a new 52-week high of USD 3.25, reflecting strong performance in the Pharmaceuticals and Biotechnology sector. The company has seen a 77.91% growth over the past year, significantly outperforming the S&P 500, and maintains solid financial metrics, including a P/E ratio of 10.00."
      },
      {
        "title": "Is CytomX Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cytomx-therapeutics-inc-technically-bullish-or-bearish-3547521",
        "imagepath": "",
        "date": "2025-09-20 19:57:22",
        "description": "As of 24 July 2025, the technical trend for CytomX Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness, while the weekly MACD and Bollinger Bands show mildly bearish signals. The monthly MACD is mildly bullish, but the RSI indicates a bearish trend. The stock has performed well year-to-date with a return of 98.06% compared to the S&P 500's 12.22%, but it has underperformed over longer periods, particularly in the 5-year and 10-year comparisons...."
      },
      {
        "title": "Is CytomX Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cytomx-therapeutics-inc-overvalued-or-undervalued-3543865",
        "imagepath": "",
        "date": "2025-09-20 18:31:05",
        "description": "As of 3 September 2025, the valuation grade for CytomX Therapeutics, Inc. has moved from attractive to very attractive, indicating a significant improvement in its valuation outlook. The company appears to be undervalued, particularly given its P/E ratio of 10, which is favorable compared to the industry average, and a PEG ratio of 0.14, suggesting strong growth potential relative to its price. Additionally, the EV to EBITDA ratio stands at 9.07, further supporting the undervaluation thesis.\n\nIn comparison to its peers, CytomX Therapeutics shows a much lower P/E ratio than Chimerix, Inc. at -8.6897 and a more favorable EV to EBITDA than Aquestive Therapeutics, Inc. at -12.8252, highlighting its relative strength in valuation metrics. While the stock has experienced a YTD return of 98.06% compared to the S&P 500's 12.22%, it has struggled in the longer term, with a 5Y return of -72.43% versus the S&P 500's 9..."
      }
    ],
    "total": 14,
    "sid": "1238937",
    "stock_news_url": "https://www.marketsmojo.com/news/cytomx-therapeutics-inc-1238937"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

CytomX Therapeutics Hits New 52-Week High of $4.62, Up 157%

2025-11-07 16:09:15

CytomX Therapeutics, Inc. has achieved a new 52-week high, reflecting a substantial increase in stock performance over the past year. The company, operating in the Pharmaceuticals & Biotechnology sector, boasts strong financial metrics, including a notable return on equity and a unique financial structure, underscoring its competitive position.

CytomX Therapeutics Hits New 52-Week High of $4.18, Up 150.92%

2025-11-05 16:49:25

CytomX Therapeutics, Inc. achieved a new 52-week high of USD 4.18 on November 4, 2025, reflecting a significant annual stock performance increase. The company, with a market cap of USD 360 million, demonstrates strong financial metrics, including a favorable P/E ratio and a high return on equity.

CytomX Therapeutics Hits New 52-Week High at $4.16

2025-11-04 17:59:44

CytomX Therapeutics, Inc. achieved a new 52-week high of USD 4.16 on November 3, 2025, reflecting a 141.1% increase over the past year. With a market cap of USD 360 million, the company demonstrates strong financial metrics, including a 40.02% return on equity and a debt-to-equity ratio of -1.27.

CytomX Therapeutics Hits New 52-Week High at $3.51, Up 109.82%

2025-10-15 17:07:52

CytomX Therapeutics, Inc. achieved a new 52-week high of USD 3.51 on October 14, 2025, marking a significant increase from its previous low. With a market cap of USD 360 million, the company demonstrates strong profitability and a solid balance sheet, reflecting its growth in the Pharmaceuticals & Biotechnology sector.

CytomX Therapeutics Hits New 52-Week High of $3.48, Up 105.52%

2025-10-02 22:39:19

CytomX Therapeutics, Inc. achieved a new 52-week high of USD 3.48 on October 1, 2025, reflecting a 105.52% increase over the past year. With a market capitalization of USD 360 million, the company shows strong financial metrics, including a P/E ratio of 10.00 and a return on equity of 40.02%.

CytomX Therapeutics Hits New 52-Week High at $3.28

2025-10-01 16:42:32

CytomX Therapeutics, Inc. has achieved a new 52-week high of USD 3.28, reflecting a 95.71% increase over the past year. With a market capitalization of USD 360 million and a P/E ratio of 10.00, the company showcases strong financial health and effective capital management.

CytomX Therapeutics Hits New 52-Week High of $3.25, Up 77.91%

2025-09-29 14:29:15

CytomX Therapeutics, Inc. achieved a new 52-week high of USD 3.25, reflecting strong performance in the Pharmaceuticals and Biotechnology sector. The company has seen a 77.91% growth over the past year, significantly outperforming the S&P 500, and maintains solid financial metrics, including a P/E ratio of 10.00.

Is CytomX Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:57:22

As of 24 July 2025, the technical trend for CytomX Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness, while the weekly MACD and Bollinger Bands show mildly bearish signals. The monthly MACD is mildly bullish, but the RSI indicates a bearish trend. The stock has performed well year-to-date with a return of 98.06% compared to the S&P 500's 12.22%, but it has underperformed over longer periods, particularly in the 5-year and 10-year comparisons....

Is CytomX Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:31:05

As of 3 September 2025, the valuation grade for CytomX Therapeutics, Inc. has moved from attractive to very attractive, indicating a significant improvement in its valuation outlook. The company appears to be undervalued, particularly given its P/E ratio of 10, which is favorable compared to the industry average, and a PEG ratio of 0.14, suggesting strong growth potential relative to its price. Additionally, the EV to EBITDA ratio stands at 9.07, further supporting the undervaluation thesis. In comparison to its peers, CytomX Therapeutics shows a much lower P/E ratio than Chimerix, Inc. at -8.6897 and a more favorable EV to EBITDA than Aquestive Therapeutics, Inc. at -12.8252, highlighting its relative strength in valuation metrics. While the stock has experienced a YTD return of 98.06% compared to the S&P 500's 12.22%, it has struggled in the longer term, with a 5Y return of -72.43% versus the S&P 500's 9...

View All News